Trends in the approval of cancer therapies by the FDA in the twenty-first century
Emma ScottOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. [email protected]Andrea BainesCenter for Drug Evaluation and ResearchYutao GongOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USARodney MooreOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USAGülsüm Emel PamukCenter for Drug Evaluation and ResearchHaleh SaberOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USAAshim SubedeeNational Cancer InstituteMatthew D. ThompsonCenter for Drug Evaluation and ResearchWenming XiaoOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USARichard PazdurOncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USAV. Ashutosh RaoOffice of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USAJulie A. SchneiderOncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USAJulia A. BeaverOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
2023en
Ochiq kirish: yoʻq
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba